Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and […]
28 Jun 08:11 · The Markets Daily